Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01167712 · OUTCOME

Progression-Free Survival

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer · Source last updated 2026-05-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
The timeframe is from enrollment onto the study up to 3 years following enrollment.

What was measured

First progression or death for weekly paclitaxel treatment relative to standard 3 week paclitaxel. Progression is defined using response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Analysis population: Whole sample

Groups in this outcome

Arm I (Adjuvant Chemotherapy Suboptimally Debulked)

Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Bevacizumab: Given IV Carboplatin: Given IV Computed Tomography: Correlative studies Paclitaxel: Given IV

Arm II (Neoadjuvant Chemotherapy)

Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4. Bevacizumab: Given IV Carboplatin: Given IV Computed Tomography: Correlative studies Paclitaxel: Given IV Therapeutic Conventional Surgery: Undergo surgery

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Adjuvant Chemotherapy Suboptimally Debulked)346
Arm II (Neoadjuvant Chemotherapy)346

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm I (Adjuvant Chemotherapy Suboptimally Debulked)14.7Not reported13.515.8Not reported
Arm II (Neoadjuvant Chemotherapy)14.0Not reported12.715.2Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    .74
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.06
    group Description
    Estimated hazard of first progression or death for weekly paclitaxel treatment relative to standard 3 week paclitaxel.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    param Type
    Hazard Ratio (HR)
    param Value
    .89
Complete source fields
analyses
  1. ci Lower Limit
    .74
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.06
    group Description
    Estimated hazard of first progression or death for weekly paclitaxel treatment relative to standard 3 week paclitaxel.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    param Type
    Hazard Ratio (HR)
    param Value
    .89
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        13.5
        upper Limit
        15.8
        value
        14.7
      2. group Id
        OG001
        lower Limit
        12.7
        upper Limit
        15.2
        value
        14.0
denoms
  1. counts
    1. group Id
      OG000
      value
      346
    2. group Id
      OG001
      value
      346
    units
    Participants
description
First progression or death for weekly paclitaxel treatment relative to standard 3 week paclitaxel. Progression is defined using response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Bevacizumab: Given IV Carboplatin: Given IV Computed Tomography: Correlative studies Paclitaxel: Given IV
    id
    OG000
    title
    Arm I (Adjuvant Chemotherapy Suboptimally Debulked)
  2. description
    Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4. Bevacizumab: Given IV Carboplatin: Given IV Computed Tomography: Correlative studies Paclitaxel: Given IV Therapeutic Conventional Surgery: Undergo surgery
    id
    OG001
    title
    Arm II (Neoadjuvant Chemotherapy)
param Type
MEDIAN
population Description
Whole sample
reporting Status
POSTED
time Frame
The timeframe is from enrollment onto the study up to 3 years following enrollment.
title
Progression-Free Survival
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice